Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Brokerages

Shares of Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) have been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $3.33.

Several equities research analysts have weighed in on the stock. ValuEngine upgraded shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, April 30th. Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, B. Riley downgraded shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $4.00 to $1.00 in a research note on Monday, April 6th.

Several large investors have recently bought and sold shares of the company. SG Americas Securities LLC lifted its stake in shares of Eyepoint Pharmaceuticals by 90.3% during the first quarter. SG Americas Securities LLC now owns 25,061 shares of the company’s stock worth $26,000 after buying an additional 11,891 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Eyepoint Pharmaceuticals by 7.0% during the first quarter. Wells Fargo & Company MN now owns 197,833 shares of the company’s stock worth $202,000 after purchasing an additional 12,984 shares during the last quarter. Summit X LLC raised its holdings in shares of Eyepoint Pharmaceuticals by 112.5% during the first quarter. Summit X LLC now owns 25,500 shares of the company’s stock worth $26,000 after purchasing an additional 13,500 shares during the last quarter. Citigroup Inc. raised its holdings in shares of Eyepoint Pharmaceuticals by 293.6% during the fourth quarter. Citigroup Inc. now owns 21,027 shares of the company’s stock worth $33,000 after purchasing an additional 15,685 shares during the last quarter. Finally, Endurance Wealth Management Inc. raised its holdings in shares of Eyepoint Pharmaceuticals by 100.0% during the second quarter. Endurance Wealth Management Inc. now owns 40,000 shares of the company’s stock worth $30,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 54.17% of the company’s stock.

Shares of NASDAQ:EYPT opened at $0.71 on Friday. The firm has a market cap of $88.57 million, a PE ratio of -1.51 and a beta of 1.35. The firm’s 50 day simple moving average is $0.77 and its 200-day simple moving average is $1.09. The company has a debt-to-equity ratio of 3.06, a quick ratio of 4.50 and a current ratio of 4.83. Eyepoint Pharmaceuticals has a one year low of $0.66 and a one year high of $2.69.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.01). The business had revenue of $7.49 million for the quarter, compared to analysts’ expectations of $6.95 million. Eyepoint Pharmaceuticals had a negative net margin of 196.31% and a negative return on equity of 286.40%. Equities research analysts predict that Eyepoint Pharmaceuticals will post -0.35 EPS for the current fiscal year.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.

Further Reading: Why do companies engage in swaps?

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.